NTRA Form 4: Officer Sells 3,000 Shares at ~$166–$168
Rhea-AI Filing Summary
Natera, Inc. (NTRA) insider sale under 10b5-1 plan. On 09/02/2025 Solomon Moshkevich, President, Clinical Diagnostics, reported three open-market sell transactions totaling 3,000 shares executed under a Rule 10b5-1 plan adopted on 11/26/2024. The sales were reported at weighted-average prices of $165.6862, $166.39, and $167.7145, with underlying per-trade price ranges of $165.09–$168.21. Beneficial ownership reported after the trades declined from 122,569 to 120,859 shares across the transactions. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Positive
- Transactions executed under a Rule 10b5-1 plan adopted on 11/26/2024, which supports compliance with insider trading rules
- Complete disclosure of weighted-average prices and price ranges for the multiple executions
Negative
- Insider sold 3,000 shares on 09/02/2025, reducing reported direct holdings from 122,569 to 120,859 shares
- Sales may be viewed negatively by some investors despite being pre-planned (no inference of intent is made in this filing)
Insights
TL;DR: Insider executed pre-planned sales totaling 3,000 shares under a 10b5-1 plan; ownership decreased modestly.
The reported transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on 11/26/2024, which provides affirmative defense to insider trading claims when properly established. The sales on 09/02/2025 amounted to 3,000 shares sold across three tranches at weighted-average prices between $165.69 and $167.71, reducing reported direct holdings from 122,569 to 120,859 shares. As these sales were pre-planned and represent a small absolute share count for an officer-level holder, the disclosure is routine from a governance and compliance perspective.
TL;DR: Transactions appear procedural under a 10b5-1 plan; no new governance issues disclosed.
The Form 4 clearly states the trades were effectuated under a 10b5-1 plan adopted 11/26/2024, and provides weighted-average price ranges across multiple executions. The filing includes standard attestations and an attorney-in-fact signature dated 09/05/2025. There is no indication in this filing of departures, option exercises, or non-routine related-party transactions that would raise immediate governance concerns.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,290 | $165.6862 | $214K |
| Sale | Common Stock | 500 | $166.39 | $83K |
| Sale | Common Stock | 1,210 | $167.7145 | $203K |
Footnotes (1)
- The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.09 to $166.06 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.09 to $166.60 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.41 to $168.21 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
